Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans
Open Access
- 1 August 2005
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (8), 3182-3186
- https://doi.org/10.1128/aac.49.8.3182-3186.2005
Abstract
Mycobacterium ulcerans disease is common in some humid tropical areas, particularly in parts of West Africa, and current management is by surgical excision of skin lesions ranging from early nodules to extensive ulcers (Buruli ulcer). Antibiotic therapy would be more accessible to patients in areas of Buruli ulcer endemicity. We report a study of the efficacy of antibiotics in converting early lesions (nodules and plaques) from culture positive to culture negative. Lesions were excised either immediately or after treatment with rifampin orally at 10 mg/kg of body weight and streptomycin intramuscularly at 15 mg/kg of body weight daily for 2, 4, 8, or 12 weeks and examined by quantitative bacterial culture, PCR, and histopathology for M. ulcerans . Lesions were measured during treatment. Five lesions excised without antibiotic treatment and five lesions treated with antibiotics for 2 weeks were culture positive, whereas three lesions treated for 4 weeks, five treated for 8 weeks, and three treated for 12 weeks were culture negative. No lesions became enlarged during antibiotic treatment, and most became smaller. Treatment with rifampin and streptomycin for 4 weeks or more inhibited growth of M. ulcerans in human tissue, and it provides a basis for proceeding to a trial of antibiotic therapy as an alternative to surgery for early M. ulcerans disease.Keywords
This publication has 26 references indexed in Scilit:
- Sensitivity of PCR Targeting the IS 2404 Insertion Sequence of Mycobacterium ulcerans in an Assay Using Punch Biopsy Specimens for Diagnosis of Buruli UlcerJournal of Clinical Microbiology, 2005
- Pilot Randomized Double-Blind Trial of Treatment ofMycobacterium ulceransDisease (Buruli Ulcer) with Topical Nitrogen OxidesAntimicrobial Agents and Chemotherapy, 2004
- Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in MiceAntimicrobial Agents and Chemotherapy, 2002
- Aquatic Insects as a Vector for Mycobacterium ulceransApplied and Environmental Microbiology, 2002
- Pilot study of treatment of Buruli ulcer with rifampin and dapsoneInternational Journal of Infectious Diseases, 2002
- Buruli Ulcer in Ghana: Results of a National Case SearchEmerging Infectious Diseases, 2002
- Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in MiceAntimicrobial Agents and Chemotherapy, 2001
- Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisonsBMJ, 1995
- A CONTROLLED TRIAL OF THE TREATMENT OF MYCOBACTERIUM ULCERANS INFECTION WITH CLOFAZIMINEThe Lancet, 1973
- Rifampicin In Experimental Mycobacterium Ulcerans InfectionJournal of Medical Microbiology, 1972